Improved oral delivery of paclitaxel following administration in nanoemulsion formulations

被引:103
作者
Tiwari, Sandip B. [1 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA
关键词
nanoemulsions; oral absorption; P-glycoprotein; hydrophobic drugs; paclitaxel;
D O I
10.1166/jnn.2006.440
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanoemulsion formulations were designed for enhancing the oral bioavailability of hydrophobic drugs. Paclitaxel was selected as a model hydrophobic drug, which is also a substrate for the P-glycoprotein efflux system. The oil-in-water (o/w) nanoemulsions were formulated with pine nut oil as the internal oil phase, egg lecithin as the primary emulsifier, and water as the external phase. Stearylamine and deoxycholic acid were used to impart positive and negative charge to the emulsions, respectively. Nanoemulsions were prepared by sonication method and characterized for particle size and surface charge. The control and nanoemulsion formulations with tritiated [H-3]-paclitaxel were administered orally to female C57BL/6 mice and the distribution of the drug was examined. The formulated nanoemulsions had a particle size range of similar to -90-120 nm (laser diffraction method) and zeta potential values ranging from -56 mV to +34 mV. Following oral administration, a significantly higher concentration of paclitaxel was observed in the systemic circulation when administered in the nanoemulsion relative to control aqueous solution. The absorbed drug was found to be distributed in the liver, kidneys, and lungs. The results of this study suggest that nanoemulsions are promising novel formulations that can enhance the oral bioavailability of hydrophobic drugs, like paclitaxel.
引用
收藏
页码:3215 / 3221
页数:7
相关论文
共 29 条
  • [1] Bagwe RP, 2001, CRIT REV THER DRUG, V18, P77
  • [2] The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery
    Bardelmeijer, HA
    van Tellingen, O
    Schellens, JHM
    Beijnen, JH
    [J]. INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 231 - 241
  • [3] Buszello K., 2000, PHARM EMULSIONS SUSP, P191
  • [4] Charman WN, 2000, J PHARM SCI-US, V89, P967, DOI 10.1002/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO
  • [5] 2-R
  • [6] Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability
    Gao, P
    Rush, BD
    Pfund, WP
    Huang, TH
    Bauer, JM
    Morozowich, W
    Kuo, MS
    Hageman, MJ
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (12) : 2386 - 2398
  • [7] GAYSORN C, 1999, J PHARM SCI, V88, P454
  • [8] Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs
    Gershanik, T
    Benita, S
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) : 179 - 188
  • [9] Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system
    Gursoy, N
    Garrigue, JS
    Razafindratsita, A
    Lambert, G
    Benita, S
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (12) : 2411 - 2418
  • [10] Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
    Gursoy, RN
    Benita, S
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) : 173 - 182